| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 0 | 0 | - | - |
| Research and development | 3,738 | 3,600 | 3,435 | 4,932 |
| General and administrative | 2,147 | 2,091 | 2,477 | 2,172 |
| Depreciation and amortization | 21 | 29 | 31 | 31 |
| Total operating expenses | 5,906 | 5,720 | 5,943 | 7,135 |
| Loss from operations | -5,906 | -5,720 | -5,943 | -7,135 |
| Gain from change in fair value of warrant liability | -1,591 | -9,609 | -9,054 | 1,728 |
| Transaction costs allocated to warrant liabilities | 530 | 1,207 | 1,788 | 993 |
| Loss on issuance of warrant liabilities | -20,609 | -10,352 | -7,798 | -847 |
| Other income, net | 16 | 4 | 9 | 9 |
| Interest income, net | 39 | 26 | 30 | 102 |
| Net loss | -25,399 | -7,640 | -6,436 | -10,592 |
| Foreign currency translation | -6 | 0 | 3 | 14 |
| Comprehensive loss | -25,405 | -7,640 | -6,433 | -10,578 |
| Net loss per common share - basic and diluted (in dollars per share) | -0.68 | -0.49 | -0.69 | -2.85 |
| Weighted average common shares outstanding, basic and diluted (in shares) | 37,304,455 | 15,526,401 | 9,343,771 | 3,714,278 |
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)